Nexalin Technology (NXL) Non Operating Interest Expenses (2021 - 2026)
Nexalin Technology (NXL) posted Non Operating Interest Expenses of -$129.0 for Q2 2026, down 279.41% on a QoQ basis from -$34.0 in Q1 2026, and up 97.25% year-over-year from -$65.4 in Q2 2025.
Powered by 
Analysis
Nexalin Technology (NXL) Non Operating Interest Expenses (2021 - 2026) Analysis & Trends
Nexalin Technology has reported Non Operating Interest Expenses for 6 years, with the latest figure at -$129.0 in Q2 2026.
- On a quarterly basis, Non Operating Interest Expenses rose 97.25% year-over-year to -$129.0 in Q2 2026; TTM through Jun 2026 was -$2610.0, a 69.71% increase from a year earlier, with the FY2025 full-year figure at -$8240.0, down 158.06% from the prior year.
- Non Operating Interest Expenses was -$129.0 for Q2 2026 at Nexalin Technology, down from -$34.0 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $19150.0 in Q4 2023, with the low at -$4690.0 in Q2 2025.
- Average Non Operating Interest Expenses over 5 years is $4301.5, with a median of -$66.0 recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: Non Operating Interest Expenses tumbled 7006.06% in 2025, then soared 97.25% in 2026.
- Over 5 years, Non Operating Interest Expenses stood at $17302.0 in 2022, then increased by 10.68% to $19150.0 in 2023, then slumped by 109.52% to -$1823.0 in 2024, then jumped by 91.28% to -$159.0 in 2025, then advanced by 18.87% to -$129.0 in 2026.
- The last three Non Operating Interest Expenses figures came in at -$129.0 (Q2 2026), -$34.0 (Q1 2026), and -$159.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.53 Bn | 174.93 Bn | 7.27 Bn | 351.00 Mn |
| 2 | Intuitive Surgical | 127.82 Bn | 122.60 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.07 Bn | 108.25 Bn | 6.34 Bn | 186.00 Mn |
| 4 | Stryker | 104.13 Bn | 100.65 Bn | 4.50 Bn | 141.00 Mn |
| 5 | Boston Scientific | 63.40 Bn | 62.86 Bn | 3.85 Bn | 96.00 Mn |
| 6 | Edwards Lifesciences | 49.72 Bn | 45.47 Bn | 1.35 Bn | - |
| 7 | Alcon | 33.00 Bn | 31.55 Bn | 1.68 Bn | -53.00 Mn |
| 8 | Dexcom | 32.13 Bn | 30.18 Bn | 830.00 Mn | - |
| 9 | Steris | 20.71 Bn | 20.23 Bn | 684.20 Mn | 15.80 Mn |
| 10 | Nexalin Technology | 3.42 Mn | 2.41 Mn | 8,897.00 | -129.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -129.00 |
| Mar 31, 2026 | -34.00 |
| Dec 31, 2025 | -159.00 |
| Sep 30, 2025 | -2,288.00 |
| Jun 30, 2025 | -4,690.00 |
| Mar 31, 2025 | -1,103.00 |
| Dec 31, 2024 | -1,823.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -66.00 |
| Mar 31, 2024 | -304.00 |
| Dec 31, 2023 | 19,150.00 |
| Sep 30, 2023 | 5,330.00 |
| Jun 30, 2023 | 5,518.00 |
| Mar 31, 2023 | 8,837.00 |
| Dec 31, 2022 | 17,302.00 |
| Sep 30, 2022 | 10,452.00 |
| Mar 31, 2022 | 18,132.00 |
| Dec 31, 2021 | 18,439.00 |
| Sep 30, 2021 | 27,175.00 |